Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments 中文版
7 Apr, 2022 (Thursday)

            
CONCH CEMENT(914)
Analysis:
Conch Cement (914) will continue to promote domestic development, speed up the construction progress of existing projects, and make every effort to push forward its merger and acquisition projects to further improve the market layout. The Group will continue to expedite its expansion of upstream and downstream industrial chain, progress with the expansion of aggregate projects and production capacity utilization with full strength, speed up the planning for commodity concrete industry, vigorously promote the development of new energy industry, to create new industrial growth engines. The Group will steadily promote overseas development and proactively build a diversified cooperation model. As at 31 December 2021, the Group's production capacity of clinker, cement, aggregates and commodity concrete amounted to 269 milliontonnes, 384 million tonnes, 65.80 million tonnes and 14.70 million cubic meters respectively, and the installed capacity of photovoltaic power generation amounted to 200 MW. (I do not hold the above stock)
Strategy:
Buy-in Price: $42.00, Target Price: $45.00, Cut Loss Price: $40.00


INNOVENT BIO(1801)
Analysis:
Innovent (1801) has released its 2021 results that the total revenue for the year was 4.261 billion yuan, an increase of 74.1% compared with 2020. The product revenue was 4.001 billion yuan, an increase of 69.0% compared with 2020; The gross profit margin of the product was 88.6%, an increase of 3.7% compared with 2020; As of the end of 2021, it has cash of approximately US$1.415 billion, which provides a solid guarantee for the company continuous and long-term development. The improvement of revenue was driven by the strong sales growth of the main product TYVYT® (sintilimab injection), which was the leading PD-1 brand approved for three new major tumor indications and was successfully included in the NRDL , becoming the only PD-1 inhibitor that has demonstrated its clinical efficacy in first-line treatments of five high-incidence tumor types included. At the same time, the management demonstrated that in addition to TYVYT® (sintilimab injection), other products under the company have also made progress to a certain extent. Six products including Retsevmo, IBI-326 (BCMA CAR-T), IBI-306 (PCSK9), IBI-310 (CTLA-4), IBI- 344 (ROS1/NTRK), IBI-376 (PI3Kδ) are in NDA or registration/pivotal clinical. The company continues to accelerate the global innovation, establishes a global platform system, and actively carries out commercialization cooperation in worldwide. In 2021, the company has invested 2.116 billion yuan in R&D with YoY increase of 23.2%; On April 6, The National Medical Products Administration (“NMPA”) of China has approved Pemazyre® (pemigatinib) for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (“FGFR2”) fusion or rearrangement as confirmed by a validated diagnostic test that have progressed after at least one prior line of systemic therapy. In the coming two years, the number of approved products will be expanded to 10+ and another 10+ innovative pipelines with global potential are in the clinical exploration stage. Therefore, we are optimistic about the company's future growth prospects.
Strategy:
Buy-in Price: $29.55, Target Price: $31.91, Cut Loss Price: $28.37



Report Review of March 2022

Sectors:

Air & Automobiles (Zhang Jing),

TMT, Semiconductors, Consumer & Healthcare (Eric Li)

Automobile & Air (ZhangJing)

This month I released an updated reports of Shanghai International Airport (600009.CH).

Under the influence of the pandemic, the passenger throughput of airports in China reached 907 million in 2021, an increase of 5.9% over 2020, and a recovery of 67.1% in 2019, which was a 32.9% decline compared to 2019. On a closer look at markets, due to the Spring Festival travel policy and the repeated sporadic outbreaks in China, the low point of aviation demand for domestic routes appeared in February, August and November, and the high point was in March, April, May and July. As the Civil Aviation Administration of China enforced strict control over the cases imported from overseas, the number of international and regional flights has always hit a trough, with small fluctuations throughout the year. Compared to 2019, the monthly number of international and regional flights has dropped by more than 90%. Only the number of flights in April and July increased slightly compared to 2020.

Compared to other airports in China, Shanghai Pudong International Airport is more dependent on non-aviation revenue such as international routes and duty-free business rentals in terms of results. Therefore, the sharp drop in international passenger traffic has a greater impact on the airport's results. According to the result forecast released on 24 January 2022, the Company predicted losses in 2021 could reach RMB1.64 billion to RMB1.78 billion. The corresponding loss from Q1 to Q4 was RMB436 million, RMB304 million, RMB510 million and RMB390-540 million. The annual tax-free revenue was expected to approach RMB500 million, a decrease of nearly 90% compared to nearly RMB5 billion in 2019.

According to the announcement, SIA signed an agreement with the holding major shareholder SAA, in which the transaction price of 100% equity of the underlying asset Hongqiao Airport is approximately RMB14.5 billion, the transaction price of 100% equity of the logistics company is approximately RMB3.1 billion, and the transaction price of No.4 Runway in Pudong Airport is approximately RMB1.5 billion, with a total of approximately RMB19.1 billion. The listed company is expected to issue approximately 434 million shares to SAA at a price of RMB44.09 per share. Meanwhile, the Company will issue no more than approximately 128 million targeted additional shares to SAA. The scale of supporting financing will be reduced to no more than RMB5 billion.

We think that Hongqiao Airport, which mainly engages in domestic routes, has quick business recovery. In the long run, it has good development prospects and strong profitability. The injection into the listed company will realise the re-integration and optimization of route resources. Affected by the pandemic, Pudong Airport, which mainly focuses on international routes, has high operating costs. In order to utilize resources more rationally and efficiently, Shanghai Airport has tried to divert a large number of idle international time resources to the domestic market, so that the passenger flow of Pudong Airport will recover faster. In addition, the reorganisation will also incorporate the logistics and cargo business, which will help improve the air cargo hub network, expand multimodal transportation, and optimize the cargo layout of Hongqiao Airport and Pudong Airport.

TMT, Semiconductors, Consumer, Healthcare (Eric Li)

This month I released an updated report of Xtep International (1368.HK).

Xtep announced a positive profit alert, and is expected to record a significant increase of not less than 70% in its consolidated profit attributable to ordinary equity holders for the year 2021 as compared to that for the year 2020.

In addition, Xtep also announced the operation data of 4Q2021. Xtep's core brand products retail sell-through (including offline and online channels) grew by 20%-25% (mid-teens growth in 3Q2021), retail discount level stayed at 25%-20%, and inventory turnover was about 4 months, which was flat QoQ. The core brand products retail sell-through increased by more than 30% in 2021, which was better than a high single-digit growth in the same period last year. The inventory turnover was about ~4 months, better than ~5 months in 2020.

A strong increase in consolidated revenue for the 2021 driven by: (1) an over 30% growth in core Xtep brand's revenue in second half of 2021 due to robust sales orders from distributors following our successful launch of signature functional and lifestyle products and retail channel upgrade during the Year; (2) accelerated revenue growth of the core Xtep brand's e-commerce and kids` businesses given the respective completed restructurings from branding, products to operations. An expansion in the gross profit margin of the core Xtep brand primarily attributable to (1) our continual effort in product innovations and better product offerings; and (2) a lower base of comparison triggered by the one-off inventory buy-back in 1H2020.

Management mentioned an accelerated growth in FY2021E, which was a result of core brand channel upgrades, ramp up of 9th generation stores, focus on retail experience & launch brand story, which increasing the associated purchase rate and sales per unit area. Xtep's ASP continued to rise as product and brand upgrades, including the launch of professional running shoes such as 160X and 260X series, and premium XDNA apparel such as the cross-over with Shaolin. In addition, kids/online grew faster after the completion of restructuring.

Management also mentioned that Product sold-out rate remained robust, with 1Q2021 and 2Q2021's >80%, 3Q2021's close to 80% and 4Q2021's close to 60%. The RSV growth momentum remained from Jan to date, discount & channel inventory remained at a healthy level.

Management noted that this strong growth momentum should have continued into 2022 year-to-date, as the 1Q-3Q22 procurement orders from distributors witnessed ~30% YoY growth. Management expects the core brand topline growth will be >30% in 1H22 and >25% for 2022 as the base is relatively high in 2021H2. Revenue growth for athleisure brands (K-Swiss, Palladium) and professional sports brands (Saucony, Merrell) to reach at least 30% and 50% respectively, in 2022.

Click Here for PDF format...




Writer Info
Research Team
Tel: + (852) 2277 6555
Email:
research@phillip.com.hk

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the “Group”) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products’ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

版權所有, 翻印必究。

Copyright(C) 2022 Phillip Securities (HK) Ltd. All Rights Reserved.